News

Vemurafenib's Efficacy in Melanoma Wanes Over Time

Publish date: July 3, 2012

 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Chapman disclosed that he receives honoraria and research funding from Roche/Genentech. The trial was sponsored by Hoffman-LaRoche. Dr. Atkins disclosed that he is a consultant to Bristol-Myers Squibb, Celgene, Curetech, Genentech, Merck, Novartis, and Prometheus.

This article was updated on July 3, 2012.

Pages

Recommended Reading

Docetaxel Bests Erlotinib in EGFR Wild-Type Lung Cancer
MDedge Hematology and Oncology
Adding Carboplatin to Pemetrexed Buoys Survival in Lung Cancer Subset
MDedge Hematology and Oncology
OGX-427 Takes Aim at Novel Target in Prostate Cancer
MDedge Hematology and Oncology
AMA Delegates Slam PSA, Mammography Screening Recs
MDedge Hematology and Oncology
Lower Dose Keeps Cabozantinib Alive in Prostate Cancer
MDedge Hematology and Oncology
Cancer More Common in People With Sleep Apnea
MDedge Hematology and Oncology
FDA Panel Backs MarginProbe Breast Cancer Detection Device
MDedge Hematology and Oncology
EMA Recommends Everolimus for Breast Cancer
MDedge Hematology and Oncology
Is Tamoxifen Pharmacogenetics Clinically Relevant?
MDedge Hematology and Oncology
Azacitidine-Gemtuzumab Combo Effective in Good-Risk AML
MDedge Hematology and Oncology